Major gaps in our understanding of the leukodystrophies result from their rarity and the lack of tissue for the interdisciplinary studies required to extend our knowledge of the pathophysiology of the diseases. This study details the natural evolution of changes in the CNS of the shaking pup (shp), a model of the classical form of the Xlinked disorder Pelizaeus-Merzbacher disease, in particular in glia, myelin, and axons, which is likely representative of what occurs over time in the human disease. The mutation in the proteolipid protein gene, PLP1, leads to a delay in differentiation, increased cell death, and a marked distension of the rough endoplasmic reticulum in oligodendrocytes. However, over time, more oligodendrocytes differentiate and survive in the spinal cord leading to an almost total recovery of myelination, In contrast, the brain remains persistently hypomyelinated. These data suggest that shp oligodendrocytes may be more functional than previously realized and that their early recruitment could have therapeutic value.
Introduction
Pelizaeus-Merzbacher disease (PMD) is a rare, X-linked recessive myelin disorder of young boys that results from mutations or duplications of the proteolipid protein gene (PLP1) (Hodes et al., 1993; Cailloux et al., 2000; Koeppen and Robitaille, 2002; Hudson, 2003; Garbern, 2007) . The majority of boys have duplications of the gene, with the number of extra copies of the gene dictating the severity of the disease (Harding et al., 1995; Inoue et al., 1999; Mimault et al., 1999; Wolf et al., 2005) . PMD presents a heterogeneous clinical picture. In the most severe, or connatal, form of the disease, death usually occurs in the first decade and sometimes as early as the first few weeks of life. The 'classical' form of PMD also presents early in life, but affected boys can live into the 2nd-6th decade with significant, though variable, neurological deficits (Koeppen and Robitaille, 2002) . At the opposite end of the spectrum, spastic paraplegia Type 2 (SPG-2), an allelic form of the disorder, has a much milder phenotype and affected boys can live up to the 6-7th decade (Saugier-Verber et al., 1994; Cailloux et al., 2000) . As with many rare human neurologic diseases, gaps in our understanding of PMD exist because of a lack of numbers of patients to study, the phenotypic variation in the disease, and a dearth of tissue for microscopy, biochemical, and molecular studies. PMD, however, has a significant number of animal models that have known mutations in Plp1 though most are short lived (Griffiths et al., 1998) . These models are part of a larger group of animals known as the myelin mutants (Duncan, 1995; Lunn et al., 1995; Werner et al., 1998; Duncan et al., 2011) . The first X-linked mutant which was proven to have a mutation of Plp1 was the jimpy (jp) mouse (Nave et al., 1986) . Jimpy and its alleles, jpmsd and jp-4J die early (21 to 25 days of age), while the jp rsh (rumpshaker) mouse has a much milder phenotype and a longer lifespan (Werner et al., 1998) . The first three mice are similar in phenotype to connatal PMD (the jpmsd mutation has been described in a connatal PMD patient (Komaki et al., 1999) ), while jprsh , given its mild myelin defect, resembles SPG-2 (the jprsh mutation has been found in a boy with SPG-2 (Kobayashi et al., 1994)). The myelindeficient rat (md) is similar to jp and dies at 21-25 days, but is even more severely dysmyelinated (Dentinger et al., 1982; Jackson and Duncan, 1988) . A mutant rabbit, known as paralytic tremor (pt), also has a mutation in PLP1 but has a milder phenotype (Tosic et al., 1994; Sypecka and Domanska-Janik, 2005) . However, perhaps the most useful model of PMD is the canine mutant known as the shaking pup (shp) (Griffiths et al., 1981a (Griffiths et al., , 1981b Duncan and Griffiths, 1983; Duncan, 1995) . As a large animal model of PMD, the shp provides ideal opportunities to study the evolution of changes in the CNS of a naturally occurring mutant as it lives up to two years or more. Therefore, it is possible to study the long-term survival of oligodendrocytes (OLs), or their
